Comerica Bank Has $1.90 Million Position in Cambrex Co. (NYSE:CBM)

Share on StockTwits

Comerica Bank cut its holdings in shares of Cambrex Co. (NYSE:CBM) by 5.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,823 shares of the biotechnology company’s stock after selling 2,002 shares during the period. Comerica Bank’s holdings in Cambrex were worth $1,899,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. BlackRock Inc. boosted its position in Cambrex by 2.7% during the 2nd quarter. BlackRock Inc. now owns 5,001,164 shares of the biotechnology company’s stock worth $234,103,000 after buying an additional 132,617 shares during the period. Vanguard Group Inc. boosted its position in Cambrex by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,504,246 shares of the biotechnology company’s stock worth $164,034,000 after buying an additional 42,200 shares during the period. Northern Trust Corp boosted its position in Cambrex by 1.9% during the 2nd quarter. Northern Trust Corp now owns 638,239 shares of the biotechnology company’s stock worth $29,877,000 after buying an additional 12,111 shares during the period. Granite Investment Partners LLC boosted its position in Cambrex by 1.9% during the 2nd quarter. Granite Investment Partners LLC now owns 454,258 shares of the biotechnology company’s stock worth $21,264,000 after buying an additional 8,494 shares during the period. Finally, Public Employees Retirement Association of Colorado boosted its position in Cambrex by 12.3% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 445,305 shares of the biotechnology company’s stock worth $20,845,000 after buying an additional 48,935 shares during the period.

Several equities research analysts recently commented on CBM shares. ValuEngine downgraded shares of Cambrex from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 9th. Zacks Investment Research downgraded shares of Cambrex from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Craig Hallum downgraded shares of Cambrex from a “buy” rating to a “hold” rating and set a $60.00 target price on the stock. in a research report on Monday, August 12th. Finally, William Blair downgraded shares of Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 target price on the stock. in a research report on Wednesday, August 7th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Cambrex presently has an average rating of “Hold” and a consensus target price of $54.83.

NYSE:CBM opened at $59.86 on Friday. The firm’s 50 day simple moving average is $59.67 and its 200 day simple moving average is $51.56. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.37 and a quick ratio of 1.70. Cambrex Co. has a one year low of $33.80 and a one year high of $60.29. The company has a market cap of $2.02 billion, a PE ratio of 21.61, a P/E/G ratio of 4.67 and a beta of 2.17.

Cambrex Company Profile

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Further Reading: What are convertible shares? 

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Short Interest in Modine Manufacturing Co.  Rises By 22.4%
Short Interest in Modine Manufacturing Co. Rises By 22.4%
Short Interest in RADCOM Ltd.  Increases By 23.4%
Short Interest in RADCOM Ltd. Increases By 23.4%
Gartner Inc  Expected to Announce Earnings of $0.85 Per Share
Gartner Inc Expected to Announce Earnings of $0.85 Per Share
Banca  Price Down 0.2% Over Last Week
Banca Price Down 0.2% Over Last Week
AmonD  Price Reaches $0.0018
AmonD Price Reaches $0.0018
DAPS Coin Reaches One Day Volume of $12,088.00
DAPS Coin Reaches One Day Volume of $12,088.00


© 2006-2019 Ticker Report